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OBJECTIVE — We explored whether cardiovascular disease (CVD) risk and the effects of
fenoﬁbrate differed in subjects with and without metabolic syndrome and according to various
features of metabolic syndrome deﬁned by the Adult Treatment Panel III (ATP III) in subjects
with type 2 diabetes in the Fenoﬁbrate Intervention and Event Lowering in Diabetes (FIELD)
study.
RESEARCH DESIGN AND METHODS — The prevalence of metabolic syndrome and
its features was calculated. Cox proportional models adjusted for age, sex, CVD status, and
baseline A1C levels were used to determine the independent contributions of metabolic syn-
drome features to total CVD event rates and the effects of fenoﬁbrate.
RESULTS — More than 80% of FIELD participants met the ATP III criteria for metabolic
syndrome. Each ATP III feature of metabolic syndrome, apart from increased waist circumfer-
ence, increased the absolute risk of CVD events over 5 years by at least 3%. Those with marked
dyslipidemia (elevated triglycerides 2.3 mmol/l and low HDL cholesterol) were at the highest
riskofCVD(17.8%over5years).FenoﬁbratesigniﬁcantlyreducedCVDeventsinthosewithlow
HDL cholesterol or hypertension. The largest effect of fenoﬁbrate to reduce CVD risk was
observed in subjects with marked dyslipidemia in whom a 27% relative risk reduction (95% CI
9–42, P  0.005; number needed to treat  23) was observed. Subjects with no prior CVD had
greater risk reductions than the entire group.
CONCLUSIONS — Metabolic syndrome components identify higher CVD risk in individ-
uals with type 2 diabetes, so the absolute beneﬁts of fenoﬁbrate are likely to be greater when
metabolic syndrome features are present.
The highest risk and greatest beneﬁts of fe-
noﬁbrate are seen among those with marked
hypertriglyceridemia.
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S
ubjects with metabolic syndrome
have a higher risk for future cardio-
vascular disease (CVD) events and
are more likely to develop diabetes (1).
The various components of metabolic
syndrome (abdominal obesity, dyslipide-
mia, hypertension, and glucose deregula-
tion) confer differential risk for CVD
based on the extent to which they deviate
from healthy normality. The guidelines
most commonly used clinically to deﬁne
metabolic syndrome are the National
Cholesterol Education Program Adult
Treatment Panel III (ATP III) guidelines
(2).Theexactroleofeachindividualmet-
abolic syndrome component in modify-
ing risk once diabetes is present has
varied in previous studies (3,4).
The Fenoﬁbrate Intervention and
Event Lowering in Diabetes (FIELD)
study was designed to assess the long-
term effect of fenoﬁbrate on CVD events
in subjects with type 2 diabetes (5–7).
The cohort of 9,795 subjects followed for
an average of 5 years was sufﬁcient to ex-
plore whether CVD event rates were in-
creased in subjects with or without
various metabolic syndrome features. Be-
cause fenoﬁbrate modiﬁes lipid parame-
ters by changing LDL particle
morphology, increasing HDL cholesterol,
and reducing triglycerides, CVD event
rates may be reduced to a larger degree in
those with metabolic syndrome features
reﬂecting a more atherogenic lipid proﬁle
at baseline.
Inthisarticle,weexploredtheclinical
relevance of metabolic syndrome and its
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lished and whether reductions in CVD
event rates with fenoﬁbrate differ accord-
ing to the presence of metabolic syn-
drome or its particular features. We also
explored the value of a higher cut point
for marked dyslipidemia, using an ele-
vated triglyceride level (2.3 mmol/l) ei-
ther alone or in combination with a low
plasma HDL cholesterol level as deﬁned
in the Helsinki Heart Study (HHS) (8).
RESEARCH DESIGN AND
METHODS— A detailed description
of the FIELD study design was published
previously (5,7). The prevalence of indi-
vidual metabolic syndrome components
according to the modiﬁed ATP III deﬁni-
tion (1) was determined as follows: 1) in-
creased blood pressure was deﬁned as the
patient stating a history of hypertension
with documentation of hypertensive
medicationuseorasmeanbloodpressure
values (over three baseline visits)
130/85 mmHg; 2) a low HDL choles-
terol level was deﬁned as 1.03 mmol/l
formenand1.29mmol/lforwomen;3)
an elevated triglyceride level was deﬁned
as 1.7 mmol/l; and 4) increased waist
circumferencewasdeﬁnedas102cmin
men and 88 cm in women. Metabolic
syndrome was present when at least three
features (type 2 diabetes plus at least two
other features) were found at baseline.
Dyslipidemia was characterized by ele-
vated triglyceride and low HDL choles-
terol levels in combination. Marked
hypertriglyceridemia and marked dyslip-
idemia were deﬁned as triglyceride levels
2.3 mmol/l alone or with a low HDL
cholesterol level, respectively.
CVD event rates were measured in
subjects without prior CVD (n  7,664,
78.2%) and in subjects with documented
CVD (n  2,131, 21.8%), according to
features of metabolic syndrome, and in
men(n6,138,62.7%)andwomen(n
3,657, 37.3%). The effect of fenoﬁbrate
according to baseline HDL cholesterol
and triglyceride levels was also reported
byprespeciﬁedcutpoints,corresponding
to approximate tertiles.
Statistical analyses
The main hypothesis was that individuals
with metabolic syndrome would obtain
greater beneﬁts from fenoﬁbrate than
those without metabolic syndrome. All
analyses concerning treatment were per-
formed on an intention-to-treat basis. All
statistical inferences were drawn using a
two-sided P value of 0.05. Cox propor-
tionalhazardsanalyseswereusedtocom-
pute hazard ratios (HRs) and 95% CIs to
assesstheeffectsoffenoﬁbrateonthetime
to ﬁrst CVD event, with P values com-
puted using Wald tests and trend tests
where appropriate. Individual Cox mod-
els were ﬁtted within prespeciﬁed sub-
groups of sex, prior CVD status, features
of the modiﬁed ATP III metabolic syn-
drome deﬁnition, and approximate ter-
tiles of baseline HDL cholesterol and
triglyceride levels. A multivariable model
was ﬁtted simultaneously, with adjust-
ment for the features of metabolic syn-
drome (using categorical variables) and
baseline A1C, age, sex, prior CVD status,
and treatment allocation. Signiﬁcant in-
teractions are presented as individual ef-
fects within subgroups, with Wald tests
for each pair simultaneously against the
null hypothesis. Conﬁdence intervals for
number needed to treat were found by
transformingCIsforriskreductions,with
Pearson’s 
2 tests used for P values. Re-
sults are unadjusted for multiple compar-
isons. All statistical analyses were
performed using SAS (version 9.1; SAS
Institute, Cary, NC).
RESULTS
Prevalence of metabolic syndrome
features and corresponding CVD
event rates
Of the 4,900 subjects allocated to pla-
cebo, 4,103 had metabolic syndrome and
797 did not, and of the 4,895 subjects
allocated to fenoﬁbrate, 4,080 had meta-
bolic syndrome and 815 did not. More
than 80% (n  8,183) of the participants
met the ATP III criteria for metabolic syn-
drome, a ﬁnding that was largely driven
by the high prevalence of increased blood
pressure and increased waist circumfer-
ence measurements, particularly among
women.MorethanhalfoftheFIELDpop-
ulation had low plasma HDL cholesterol
or elevated triglyceride levels that met the
criteria. All metabolic syndrome features
were more prevalent in women than in
men.Markedhypertriglyceridemia(2.3
mmol/l) occurred in approximately one-
quarter of both men (n  1,197) and
women (n  817) and in approximately
one-ﬁfth of men and women when com-
bined with low HDL cholesterol (Table
1).
In those with metabolic syndrome,
the 5-year placebo group CVD event rate
was14.5%comparedwitharateof11.3%
for those not meeting the criteria (n 
1,612; P  0.0001) (Table 1, Fig. 1).
Among individuals with any particular
feature of metabolic syndrome, the CVD
event rates were similar to those seen in the
overall population, varying from 13.3% for
high waist circumference to 15.4% for ele-
vatedtriglyceridelevels(Table1).However,
each additional feature of metabolic syn-
drome to diabetes resulted in a cumula-
tively higher risk of CVD events (Fig. 1A).
Low HDL cholesterol or elevated triglycer-
ide levels as risk determinants for CVD
appearedtobemorestronglydependenton
whether metabolic syndrome was present
than hypertension or increased waist
circumference (Fig. 1B). Furthermore, the
presence of each ATP III feature for meta-
bolic syndrome compared with its absence,
apart from increased waist circumference,
increased the absolute risk of CVD events
over 5 years by 3% (Fig. 2). Those with
marked dyslipidemia (triglycerides 2.3
mmol/l with low HDL cholesterol levels)
had the highest risk of CVD (17.8% over 5
years).
Among individuals with any particu-
lar feature of metabolic syndrome, as
among those with metabolic syndrome
and in the overall population, men had
approximately twice the risk of women
forCVDevents.Inbothsexes,thehighest
event rates were seen in the setting of
marked dyslipidemia (Table 1). As ex-
pected, those with prior CVD had a much
higherriskforCVDevents(2.5-fold)than
those with no prior CVD across all fea-
tures of metabolic syndrome (Table 1).
Among subjects with metabolic syn-
drome, the CVD event rate for the 1,846
subjects with prior CVD was 25.5% and
for those 6,337 subjects without prior
CVD was 10.3%. Event rates were higher
in both groups when marked dyslipide-
mia was present, at 29.8% and 11.0%,
respectively (P  0.01).
Effects of fenoﬁbrate to reduce CVD
risk
Among individuals with metabolic syn-
drome, fenoﬁbrate reduced the 5-year
CVD risk from 14.5 to 13.1%, represent-
ing a proportional risk reduction of 11%
(adjusted HR 0.89 [95% CI 0–21%], P 
0.052; absolute risk reduction 1.4%) (Ta-
ble 2). In the smaller group without met-
abolic syndrome, fenoﬁbrate reduced
CVD risk from 11.3 to 9.7%, a 12% pro-
portional reduction (0.88 [19 to 35%],
P  0.375; 1.6%); these relative risk re-
ductions were almost identical (Pinteraction
value  0.91) (Fig. 2).
The effects of fenoﬁbrate were similar
among individuals with and without any
Fenoﬁbrate and CVD risk in type 2 diabetes
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the adjusted HRs were only indepen-
dentlysigniﬁcantinthosewithalowHDL
cholesterol level and hypertension, there
was no evidence of signiﬁcant statistical
interactions(Fig.2).Incontrast,thetreat-
ment effect appeared to be greater in
womenthaninmenandinprimaryrather
than in secondary prevention of CVD.
This was apparent in the overall popula-
tion, among those with metabolic syn-
drome, and among those with any feature
of metabolic syndrome. Among those
with metabolic syndrome, fenoﬁbrate re-
duced the proportional risk for CVD by
18%inwomencomparedwith7%inmen
and by 17% in primary prevention and
1% in secondary prevention; however,
the differences between the sexes and by
history of CVD were not statistically
signiﬁcant.
Effects of fenoﬁbrate in marked
dyslipidemia
In all subgroups (women and men and
primary and secondary prevention), the
effects of fenoﬁbrate were larger when
marked hypertriglyceridemia or marked
dyslipidemia was present. In those with
marked dyslipidemia, fenoﬁbrate re-
duced CVD rates by 30 and 24% in
women and men, respectively, and by 40
and 12% in primary and secondary pre-
vention, respectively, being separately
statistically signiﬁcant for men and pri-
mary prevention (Table 2). Indeed, the
overall effect of fenoﬁbrate in the pres-
ence of marked dyslipidemia was larger
thanthatinallothergroups,withborder-
linesigniﬁcanceoftreatmentbygroupin-
teraction: marked dyslipidemia group:
27% risk reduction (adjusted HR 0.73
[95% CI 0.58–0.91], P  0.005); all oth-
ers: 6% risk reduction (0.94 [0.83–1.06],
P  0.321; Pinteraction  0.053) (Fig. 2).
The absolute risk reduction in the pres-
ence of marked dyslipidemia was 4.3%
(from 17.8 to 13.5%), compared with
0.8% (from 13.0 to 12.2%) in its absence
(Fig. 2). This corresponds to a number
needed to treat of 23 compared with 143,
respectively. The effects of treatment ac-
cording to the presence or absence of
marked dyslipidemia were signiﬁcantly
different when only those subjects with
metabolic syndrome were examined (P 
0.045) (data not shown).
FenoﬁbratereducedtotalCVDevents
by 11% (95% CI 0.80–0.99, P  0.035)
(Fig. 2). In addition, the effect of fenoﬁ-
brate among individuals with metabolic
syndrome was close to being indepen-
dently signiﬁcant (P  0.052) (Fig. 2),
although not separately signiﬁcant in its
absence (P  0.375). Nevertheless, there
was no signiﬁcant interaction between
those with and without metabolic syn-
drome (P  0.910).
Contribution of metabolic syndrome
features to CVD risk
HDL cholesterol levels (P  0.003), sys-
tolic blood pressure, and triglyceride lev-
els (P  0.0004) made independent
signiﬁcant contributions to CVD risk (af-
teradjustmentforage,sex,priorCVDsta-
tus, baseline A1C, and LDL cholesterol),
whereas waist circumference (P  0.61)
did not (Fig. 3). The effect of systolic
blood pressure was signiﬁcantly stron-
ger in primary than in secondary pre-
vention (Pinteraction  0.019). Those
with low HDL cholesterol levels had a
22% higher risk of CVD, and those with
high triglyceride levels had a 24%
higher risk. Elevated blood pressure al-
most doubled risk (93% increase) in
primary prevention, whereas the 24%
estimated risk increase in secondary
prevention was not statistically signiﬁ-
Table 1—Prevalence rates and CVD event rates over 5 years according to ATP III features of metabolic syndrome, various baseline charac-
teristics, and treatment assignment
Men Women
No prior
CVD Prior CVD Placebo Fenoﬁbrate Total
n 6,138 3,657 7,664 2,131 4,900 4,895 9,795
Prevalence rates
Increased waist circumference 3,613 (58.9) 3,034 (83.0) 5,220 (68.1) 1,427 (67.0) 3,320 (67.8) 3,327 (68.0) 6,647 (67.9)
Raised TGs (1.7 mmol/l) 3,073 (50.1) 2,020 (55.2) 3,926 (51.2) 1,167 (54.8) 2,525 (51.5) 2,568 (52.5) 5,093 (52.0)
Reduced HDL cholesterol level 3,365 (54.8) 2,455 (67.1) 4,477 (58.4) 1,343 (63.0) 2,896 (59.1) 2,924 (59.7) 5,820 (59.4)
Increased blood pressure 5,050 (82.3) 3,131 (85.6) 6,300 (82.2) 1,881 (88.3) 4,095 (83.6) 4,086 (83.5) 8,181 (83.5)
Metabolic syndrome criteria fulﬁlled 4,870 (79.3) 3,313 (90.6) 6,337 (82.7) 1,846 (86.6) 4,103 (83.7) 4,080 (83.4) 8,183 (83.5)
Raised TGs 1.7 mmol/l and
reduced HDL cholesterol level
2,133 (34.8) 1,577 (43.1) 2,816 (36.7) 894 (42.0) 1,824 (37.2) 1,886 (38.5) 3,710 (37.9)
Raised TGs (2.3 mmol/l) 1,556 (25.4) 961 (26.3) 1,912 (24.9) 605 (28.4) 1,222 (24.9) 1,295 (26.5) 2,517 (25.7)
Raised TGs 2.3 mmol/l and low
HDL cholesterol
1,197 (19.5) 817 (22.3) 1,521 (19.8) 493 (23.1) 970 (19.8) 1,044 (21.3) 2,014 (20.6)
CVD event rates
Increased waist circumference 585 (16.2) 260 (8.6) 510 (9.8) 335 (23.5) 443 (13.3) 402 (12.1) 845 (12.7)
Raised TGs (1.7 mmol/l) 557 (18.1) 180 (8.9) 423 (10.8) 314 (26.9) 388 (15.4) 349 (13.6) 737 (14.5)
Reduced HDL cholesterol 588 (17.5) 228 (9.3) 468 (10.5) 348 (25.9) 437 (15.1) 379 (13.0) 816 (14.0)
Increased blood pressure 878 (17.4) 284 (9.1) 678 (10.8) 484 (25.7) 612 (14.9) 550 (13.5) 1,162 (14.2)
Metabolic syndrome criteria fulﬁlled 835 (17.1) 291 (8.8) 655 (10.3) 471 (25.5) 593 (14.5) 533 (13.1) 1,126 (13.8)
Raised TGs (1.7 mmol/l) and
reduced HDL cholesterol
405 (19.0) 155 (9.8) 318 (11.3) 242 (27.1) 296 (16.2) 264 (14.0) 560 (15.1)
Raised TGs (2.3 mmol/l) 285 (18.3) 98 (10.2) 206 (10.8) 177 (29.3) 210 (17.2) 173 (13.4) 383 (15.2)
Raised TGs 2.3 mmol/l and low
HDL cholesterol
226 (18.9) 88 (10.8) 167 (11.0) 147 (29.8) 173 (17.8) 141 (13.5) 314 (15.6)
Overall 980 (16.0) 315 (8.6) 756 (9.9) 539 (25.3) 683 (13.9) 612 (12.5) 1,295 (13.2)
Data are n (%). TGs, triglyceride levels.
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no effect on CVDrisk in this cohort. For
comparison, a 1% higher A1C at base-
line conferred a risk increase of 18%
(95% CI 13–24%, P  0.0001) in pri-
mary prevention and 8% (2–15%; P 
0.0128) in secondary prevention. Feno-
ﬁbratereducedriskby12%afteradjust-
ment for all of the above factors (P 
0.026) (Fig. 3). The estimated area un-
derthecurveforthisriskmodelaccord-
ing to the c statistic was 70%.
CONCLUSIONS — The clustering of
riskfactorsdescribedasconstitutingmet-
abolicsyndromeismostimportantinpre-
dicting the incidence of diabetes,
althoughitalsoidentiﬁesindividualswho
have an increased risk of CVD events
(9,10). The high prevalence of metabolic
syndromeseenintheFIELDpopulationis
similar to that observed in the U.S. Na-
tional Health and Nutrition Examination
Survey III survey and also in individuals
with newly diagnosed diabetes (11,12).
The CVD event rates in the FIELD popu-
lation with metabolic syndrome and with
individual features of metabolic syn-
drome(elevatedbloodpressure,lowHDL
cholesterollevel,andelevatedtriglyceride
level) were signiﬁcantly higher than in
those without metabolic syndrome, indi-
cating that, even in the presence of estab-
lished type 2 diabetes, metabolic
syndrome still confers important addi-
tional prognostic information. Waist cir-
cumference(adjustedforsex)didnotadd
further prognostic information for CVD
risk.
Marked hypertriglyceridemia (2.3
mmol/l) with or without a low HDL cho-
lesterol level was associated with a higher
CVD risk than meeting the criteria for
metabolic syndrome, supporting a con-
tinuous positive relationship between tri-
glyceride levels and CVD (13). This level
of hypertriglyceridemia was associated
withincreasedCVDeventsinearlierstud-
Figure1—A:CVDeventrates(percentage)insubjectsreceivingplacebowhohaddiabetes(DM)
alone or diabetes with any of one to four additional features of metabolic syndrome. B: CVD event
rates (percentage) for subjects with hypertension, increased waist circumference, triglyceride
levels (TG) 1.7 mmol/l, and low HDL cholesterol (HDLc) levels with or without metabolic
syndrome (MS).
Table 2—Effect of fenoﬁbrate on CVD risk over 5 years according to ATP III features of metabolic syndrome
Men Women No prior CVD Prior CVD Unadjusted Adjusted*
Increased waist
circumference
0.95 (0.80–1.11) 0.80 (0.63–1.02) 0.86 (0.73–1.03) 0.96 (0.77–1.18) 0.90 (0.79–1.03) 0.90 (0.78–1.03)
Raised TGs (1.7
mmol/l)
0.92 (0.78–1.09) 0.76 (0.57–1.02) 0.83 (0.69–1.01) 0.92 (0.74–1.15) 0.88 (0.76–1.01) 0.87 (0.75–1.00)
Reduced HDL
cholesterol
0.88 (0.75–1.03) 0.80 (0.61–1.03) 0.75 (0.62–0.90)† 1.01 (0.82–1.25) 0.85 (0.74–0.97)‡ 0.86 (0.75–0.99)‡
Triglycerides (1.7
mmol/l) and reduced
HDL cholesterol
0.90 (0.74–1.09) 0.76 (0.55–1.04) 0.77(0.62–0.97)‡ 0.96 (0.75–1.24) 0.86 (0.73–1.01) 0.84 (0.71–1.00)‡
Increased blood
pressure
0.92 (0.80–1.05) 0.82 (0.65–1.04) 0.80 (0.69–0.93)† 1.04 (0.87–1.25) 0.89 (0.80–1.00) 0.88 (0.79–0.99)‡
Metabolic syndrome
criteria fulﬁlled
0.93 (0.81–1.06) 0.82 (0.65–1.03) 0.83 (0.71–0.97)‡ 0.99 (0.83–1.19) 0.90 (0.80–1.01) 0.89 (0.79–1.00)
Raised TGs (2.3
mmol/l)
0.75 (0.60–0.95)‡§ 0.79 (0.53–1.18) 0.65 (0.49–0.86)† 0.89 (0.67–1.20) 0.76 (0.62–0.93)† 0.77 (0.63–0.94)‡
Raised TGs (2.3
mmol/l) and reduced
HDL cholesterol
0.76 (0.58–0.98)‡ 0.70 (0.46–1.07) 0.60 (0.44–0.82)†§ 0.88 (0.64–1.21) 0.74 (0.59–0.92)† 0.73 (0.58–0.91)†
Whole FIELD cohort 0.92 (0.81–1.04) 0.80 (0.64–0.99)‡0.81 (0.70–0.93)† 1.02 (0.86–1.20) 0.89 (0.80–0.99)‡ 0.89 (0.80–0.99)‡
Data are HRs (95% CI). TGs, triglyceride levels. *Adjusted for sex, age at visit 1, prior CVD, and baseline A1C. Treatment effect within the speciﬁed subgroup: †P 
0.05, ‡P  0.01. §Pinteraction values compare subjects in the speciﬁed group with those who are not (P  0.05).
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dency for high nonfasting triglyceride
levels and higher numbers of remnant
particlesandmaybeassociatedwithmore
extreme abnormalities in other biological
processes (such as oxidative stress, in-
ﬂammation, and hypercoagulability),
leadingtomoreaggressiveatherosclerosis
(12,14,15).
Accordingly, with higher baseline
risk, the absolute beneﬁts of fenoﬁbrate
are likely to be greater when metabolic
syndrome features are present. Whereas
the effect of fenoﬁbrate on CVD events
was statistically signiﬁcant overall, it was
of only borderline signiﬁcance in the
groupwithmetabolicsyndromeandnon-
signiﬁcant in those without, although
with similar proportional reductions.
Although LDL cholesterol levels are
effectively lowered by statins (16), ele-
vatedbaseline(17)andon-treatment(18)
triglyceride levels remain risk markers for
CVD in individuals with and without di-
abetes who are already taking statins and
are a potential target for ﬁbrate therapy.
Giventhatthelargesteffectofﬁbratesisto
lower triglyceride levels by 2 5 % ,i ti s
not surprising that individuals with ele-
vated triglyceride levels appear to obtain
Figure 3—Cox regression model for effect of metabolic syndrome features on total CVD events, adjusted for age, sex, prior CVD status, A1C, and
LDL cholesterol levels at baseline. F, female; HDLc, HDL cholesterol; M, male.
Figure 2—Forest plot of effects of fenoﬁbrate on cardiovascular events adjusted for sex, prior CVD, age at visit 1, and baseline A1C (HR and 95%
CI): ATP III waist circumference criteria (men 102 cm and women 88 cm), raised triglyceride levels (TG) (1.7 mmol/l or 2.3 mmol/l),
reducedHDLcholesterol(HDLc)levels(men1.03mmol/landwomen1.29mmol/l),andATPIIImetabolicsyndrome(MS)criteria(diabetesand
two others).
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sult is supported by ﬁndings from the
Bezaﬁbrate Infarct Prevention (BIP) study
(19) showing that ﬁbrate therapy was
more effective in treatment of individuals
with than without metabolic syndrome;
further, the BIP study and the HHS (8)
showedparticularbeneﬁtamongsubjects
with markedly elevated triglyceride lev-
els, and the Veterans Administration
High-Density Lipoprotein Intervention
Trial Intervention Trial (20) showed a re-
lation of beneﬁts to low HDL cholesterol
levels. In the FIELD study, fenoﬁbrate
had the greatest absolute beneﬁt in those
with markedly high triglyceride levels to-
gether with low HDL cholesterol levels,
nowconﬁrmingsimilarﬁndingsinapop-
ulation with type 2 diabetes and meta-
bolic syndrome. Nevertheless, because
these results are presented with P values
unadjusted for multiple comparisons,
these ﬁndings should be regarded as
exploratory.
In a short-term study, fenoﬁbrate was
effective in lowering postprandial triglyc-
eride levels, particularly when metabolic
syndrome and elevated triglyceride levels
were present. In the setting of metabolic
syndrome and hypertriglyceridemia, fe-
noﬁbrate was shown to be more effective
in reducing fasting triglyceride and in-
creasing HDL cholesterol levels and in re-
ducing postprandial triglyceride levels
and oxidized fatty acid levels, which cor-
responded with a decrease in VLDL par-
ticle size and an increase in LDL particle
size (21).
Multivariate modeling conﬁrmed the
independent contributions of HDL cho-
lesterol, triglyceride levels, and blood
pressure to CVD risk, whereas the contri-
butionfromwaistcircumferencewassub-
stantially explained by other factors.
Hypertriglyceridemia is an important
markerofCVDriskintype2diabetesand
animportantmarkerofbeneﬁtfromfeno-
ﬁbrate, even though the risk conferred
has appeared to be mediated through
other conventional factors in other set-
tings (22). These ﬁndings should interest
physicians considering lipid-lowering
therapy for patients with diabetes.
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